Ardelyx Inc
NASDAQGM:ARDX
United States / Healthcare / Biotechnology
ARDX News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
Ardelyx, Inc. (Nasdaq: NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet...
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth
On Thursday, 13 March 2025, Ardelyx (NASDAQ: ARDX) presented at the Barclays 27th Annual Global Healthcare Conference, offering insights into its strategic initiatives. The company...
Ardelyx honors inaugural Derek Forfang award winners
WALTHAM, Mass. - Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company with a market capitalization of $1.3 billion and impressive revenue growth of 168% in the last twelve...
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Ardelyx, Inc. (Nasdaq: NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet...
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty
On Wednesday, Piper Sandler reaffirmed a Neutral rating on Ardelyx, Inc. (NASDAQ:ARDX) with a consistent price target of $8.00 per share. The firm's stance remains cautious due to...
Ardelyx Inc receives Investment Bank Analyst Rating Update
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities
On Tuesday, 11 March 2025, Ardelyx Inc. (NASDAQ: ARDX) presented at the Leerink Global Healthcare Conference 2025, outlining its strategic initiatives amid both promising prospects...
Ardelyx CEO Michael Raab sells $223,198 in stock
Michael Raab, President and CEO of Ardelyx, Inc. (NASDAQ:ARDX), a biotechnology company currently valued at $1.26 billion and showing strong financial health according to...
Scotiabank sets $15 target for Ardelyx stock, sees growth potential
On Friday, Scotiabank (TSX:BNS) initiated coverage of Ardelyx, Inc. (NASDAQ:ARDX), assigning a Sector Outperform rating and establishing a price target of $15.00 per share....